Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIFAKiD-TB Trial
2023-506432-32-00Phase 4Completed
- Sponsor
- Bellvitge University Hospital
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in latent tuberculosis infection (LTBI) comparing 3HR: isoniazid + rifampicin, 3HP: isoniazid + rifapentine and 4R: rifampicin (3 arms). Primary endpoints: Treatment completion rate (3HR arm), Treatment completion rate (3HP arm) and 1 more. Started Nov 2023; status: completed.
02
Drugs
rifampicinisoniazidrifapentine
03
Conditions
latent tuberculosis infection (LTBI)
Beyond the preview
Go deeper on 2023-506432-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506432-32-00.